Adheris Health (ASX:AHE) Shares Fall as Investors React to Latest News

Sonal Goyal

26 October 2026 04:59 PM AEDT

Adheris Health (ASX:AHE) Shares Fall as Investors React to Latest News

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Adheris Health (ASX:AHE) shares traded at $0.013, down 13.33%, during the 26 October 2026 session.
Operating costs fell 37% from FY25 to FY26.
Cash was $9.5m with no Debt after the ANZ Business sale.

Adheris Health Ltd (ASX:AHE) shares traded at $0.013, down 13.33%, during the Trading session on 26 October 2026, while the S&P/ASX 200 index (XJO) stood at 8,805.30, up 0.11% or 10.10 points, at 2:06 pm. Separately, the company's latest announcement on file is dated 31 August 2026 and covers its FY26 full-year results.

Adheris Health, formerly MedAdvisor, provides patient engagement programs to pharmaceutical companies, and the release reports a year of cost reduction and lower revenue. The release is dated earlier than the session, so the share price movement and the announcement are reported as separate items.

FY26 results (31 August 2026)

Adheris reduced operating costs by 37%, migrated to a new technology platform and refreshed its Leadership team. Revenue and profitability were affected by lower customer renewals and lower bookings in the previous pharma budget cycle, its peak booking season. Cash Flow break-even was reached in Q4 FY26, and the year ended with $9.5 million of cash and no debt following the sale of the ANZ business to Jonas Software in July 2025.

CY27 pipeline

The calendar 2027 pharma planning cycle is well under way, with nearly 60% of current opportunity value in THRiV and digital engagement programs and decisions on most of the pipeline expected by December 2026. The company booked over US$3 million in win-back contracts and added eight new brands in the second half. It expects to hold cash flow break-even across the year, although quarterly cash flow may be uneven, and a Non-Executive Director was appointed on 1 July 2026.

About Adheris Health

Adheris Health Limited (ASX:AHE), based in Melbourne and formerly MedAdvisor, provides technology-based patient engagement and medication adherence programs to pharmaceutical customers, mainly in the United States.

Related sector context

Pharma Marketing budgets are set in annual planning cycles, so bookings concentrate around those decisions. The company says its CY27 decisions are due by December 2026.

The XJO was up 0.11% at 2:06 pm on the day.

Risks to weigh in

FY26 revenue and profitability were lower on reduced renewals, the company says rebuilding the revenue base is the focus for CY27, and cash flow is expected to be uneven by quarter. Shares priced at $0.013 can move sharply in either direction.

Catalysts on watch

Items to follow include pharma budget decisions by December 2026, quarterly cash flow and bookings, and win-back contract conversions.

Summing up

Adheris Health (ASX:AHE) traded 13.33% lower during the 26 October 2026 session, while its latest release, dated 31 August 2026, reported cost reductions and cash flow break-even in FY26.

FAQs

Q: How did Adheris Health (ASX:AHE) shares trade on 26 October 2026?

A: Shares traded at $0.013, down 13.33%, during the trading session, while the S&P/ASX 200 was up 0.11% at 2:06 pm.

Q: What was the cash position?

A: $9.5 million with no debt.

Q: What drove lower FY26 revenue?

A: Lower customer renewals and lower bookings in the previous pharma budget cycle.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.